CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase 1 Open-label, First-in-human, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Actinium-225-macropa-pelgifatamab (BAY 3546828) in Participants With Advanced Metastatic Castration Resistant Prostate Cancer (mCRPC)
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT06052306
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:29:08.166167+00:00
- Published At
- 2026-04-17T00:00:00+00:00
- Record Updated At
- 2026-04-17
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Metastatic Castration-resistant Prostate Cancer"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-17"- protocolSection.identificationModule.nctId
"NCT06052306"- protocolSection.identificationModule.officialTitle
"A Phase 1 Open-label, First-in-human, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Actinium-225-macropa-pelgifatamab (BAY 3546828) in Participants With Advanced Metastatic Castration Resistant Prostate Cancer (mCRPC)"- protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"- protocolSection.designModule.phases
["PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.